- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Nicolas Ferreyros: COA's 2023 Community Oncology Conference Celebrating 2 Decades of Achievements
This year's Community Oncology Conference will celebrate 2 decades of achievements in community oncology and begin to chart a path forward for the future, said Nicolas Ferreyros, managing director of policy, advocacy, and communications at Community Oncology Alliance (COA).
This year's Community Oncology Conference will celebrate 2 decades of achievements in community oncology and begin to chart a path forward for the future, said Nicolas Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance (COA).
Here's what to look forward to at the COA 2023 Community Oncology Conference, which will be held March 22-24, in Kissimee, Florida.
Transcript
What are you looking forward to at the the COA 2023 Community Oncology Conference?
This is going to be my eighth COA conference and I'm really excited about it because we're on track to be, if not 50%, higher than we were last year for attendance; that is a huge milestone for COA, not to mention the fact that it's our 20th anniversary this year.
In addition to having a bigger and better crowd than ever before, we get to celebrate the achievements of community oncology over the last 2 decades, and then also chart the path forward with new topics, new ideas, a fresh leadership. So, it's going to be a really great conference.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
